{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"1"}]}],"title":"At Least 1 TEAE Leading to Discontinuation of Study Drug"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"}]}],"title":"Capillary leak syndrome"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"}]}],"title":"Metastatic malignant melanoma"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"}]}],"title":"Pancreatitis"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"}]}],"title":"Thrombocytopenia"}],"denoms":[{"counts":[{"groupId":"OG000","value":"7"},{"groupId":"OG001","value":"2"}],"units":"Participants"}],"description":"To evaluate the safety of single agent SL-401 in an initial run-in cycle in patients with multiple myeloma (MM)","groups":[{"description":"SL-401 7 µg/kg/day in combination with pomalidomide/dexamethasone (pom/dex)\n\nSL-401 7 µg/kg/day: SL-401 7 µg/kg/day in combination with pomalidomide/dexamethasone (pom/dex)","id":"OG000","title":"SL-401 7 µg/kg/Day"},{"description":"SL-401 9 µg/kg/day in combination with pomalidomide/dexamethasone (pom/dex)\n\nSL-401 9 µg/kg/day: SL-401 9 µg/kg/day in combination with pomalidomide/dexamethasone (pom/dex)","id":"OG001","title":"SL-401 9 µg/kg/Day"}],"paramType":"COUNT_OF_PARTICIPANTS","reportingStatus":"POSTED","timeFrame":"Up to 12 Months","title":"Treatment-Emergent Adverse Events Leading to Discontinuation of Study Drug","type":"PRIMARY","unitOfMeasure":"Participants"}